Advertisement
Table 3 Adverse events occurred in at least 5% of subjects in either group a
| Event | n-CEA (n = 20) | DCEAS (n = 23) |
|---|---|---|
| Fatigue | 8 (40.0) | 11 (47.8) |
| Needling-induced discomfort | 6 (30.0) | 7 (30.4) |
| Headache | 6 (30.0) | 4 (17.4) |
| Dizziness | 1 (5.0) | 4 (17.4) |
| Nausea | 2 (10.0) | 1 (4.3) |
| Vomiting | 0 | 2 (8.7) |
| Depression deterioration | 2 (10.0) | 3 (13.0) |
| Movement disorder | 3 (15.0) | 5 (21.7) |
| Sweating | 1 (5.0) | 1 (4.3) |
| Palpitation | 1 (5.0) | 5 (21.7) |
| Insomnia | 3 (15.0) | 6 (26.1) |
| Hypersomnia | 2 (10.0) | 8 (34.8) |
